Americans share up to AstraZeneca coverage rate up to 60m – KBC


The United States will share up to 60 million doses of its AstraZeneca vaccine and other countries as it becomes available, the White House has said.

Download Mp3 or Play

The tests will be shipped in the coming months after the federal security audit.

The United States has reserves of the vaccine even though its regulators have not approved public use.

Critics have accused the government of monopolizing the vaccine, while other countries are in dire need.

Getting broken information on your Phone as it happens. Send SMS ‘NEWS’ to 20153

Last month President Joe Biden promised to share nearly four million doses of AstraZeneca vaccine with Mexico and Canada – both of which have approved the jab.

The crisis in India has also increased pressure on the Biden regime to share US health resources.

On Monday, the White House said it expects that around 10 million doses of AstraZeneca vaccine could be released by the Food and Drug Administration (FDA) when it completes its inspections in the coming weeks.

It stated that another 50 million tests were in various stages of production.

At a press conference, White House spokeswoman Jen Psaki said FDA officials would conduct a quality audit on dosage before being shipped out.

“Our team will share more details about our plans and who will receive the offer from here, but we are in the process of planning this time in time,” he added.

The United States has already announced that it will provide raw materials to Indian vaccine manufacturers as the country struggles with visa increases.

In a “warm and positive” call by Indian Prime Minister Narendra Modi on Monday, President Biden promised more emergency assistance “including oxygen-related equipment, vaccination equipment, and treatment”, a White House statement said.

Washington is also looking to distribute oxygen, Covid tests, personal protective equipment (PPE), and antiviral drugs against India’s health care.

The FDA has so far approved three vaccines against Covid- 19 – Pfizer BioNTech, Moderna, and Johnson & Johnson (Janssen). Experts say it looks like these will meet all the country’s needs and AstraZeneca’s jab may not be needed.

According to the latest statistics, more than 53% of adults have so far received at least one dose of vaccine.

(function(d, s, id) {
var js, fjs = d.getElementsByTagName(s)[0];
if (d.getElementById(id)) return;
js = d.createElement(s); = id;
js.src = “”;
fjs.parentNode.insertBefore(js, fjs);
}(document, ‘script’, ‘facebook-jssdk’));

About Anna Jebet

Leave a Reply

Your email address will not be published. Required fields are marked *